Condition
Mild Cognitive Impairment Due to Alzheimer's Disease clinical trials and research
Research outlook What's coming for Alzheimer's disease: the next 6 months to 5 yearsAs of November 12, 2026, Find a Trial lists 4 Mild Cognitive Impairment Due to Alzheimer's Disease clinical trials that are recruiting, at sites in 4 countries (most in Czechia (1), United Kingdom (1), United States (1)). By phase: Phase 3 (1), Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 4Countries
Newest Mild Cognitive Impairment Due to Alzheimer's Disease clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Urolithin A for early Alzheimer’s disease: a test with a nutritional supplement | — | Prague | Recruiting | Sep 25, 2026 |
| Treatments for sustained improvement in symptomatic Alzheimer’s disease (18 months) | Phase 3 | Cambridge and 1 other locations | Recruiting | Jul 23, 2026 |
| Spermidine to improve sleep and memory in mild cognitive impairment | — | Greifswald, Mecklenburg-Vorpommern | Recruiting | Feb 3, 2026 |
| Nasal foralumab to reduce brain inflammation in early Alzheimer’s | Phase 2 | Boston, Massachusetts | Recruiting | Jul 8, 2024 |
All recruiting trials (4)
-
Urolithin A for early Alzheimer’s disease: a test with a nutritional supplement
This trial tests whether taking urolithin A in addition to standard care helps people with early Alzheimer’s or mild cognitive impairment show better biomarkers and cognition.
-
Treatments for sustained improvement in symptomatic Alzheimer’s disease (18 months)
This trial tests whether adding atomoxetine or metformin to standard care helps people with Alzheimer’s disease or related dementia see lasting improvements over 18 months.
-
Spermidine to improve sleep and memory in mild cognitive impairment
This will see if taking daily spermidine supplements for 12 weeks improves sleep quality and sleep-related memory in older adults with MCI due to Alzheimer's disease.
-
Nasal foralumab to reduce brain inflammation in early Alzheimer’s
This trial will test whether nasal foralumab, given three times a week, can reduce brain immune inflammation and improve thinking in people aged 60–85 with mild cognitive impairment from early Alzheimer’s disease.
Related topics
Quick answers
How many Mild Cognitive Impairment Due to Alzheimer's Disease clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 4 countries. The most sites are in Czechia (1 trial), United Kingdom (1 trial), United States (1 trial), Germany (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 3: 1, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.